Ischemic StrokeCATISNCT01840072
China Antihypertensive Trial in Acute Ischemic Stroke
A study testing Active antihypertensive treatment in people with Ischemic Stroke, run by Tulane University at 1 site in China.
Trial summary
This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Ischemic Stroke
- What is being tested?
- Active antihypertensive treatment
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,071 participants
- Where
- 1 siteChina
- Study dates
- Aug 2009to May 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥22 years
- Ischemic stroke onset within 48 hours confirmed by imaging (CT scan or MRI) study
- Systolic BP≥140 and <220 mm Hg and diastolic BP≥80 mm Hg
- No contraindications to antihypertensive treatment
- Able and willing to sign informed consent by patients or their direct family members
Who cannot join
- Individuals with hemorrhagic stroke
- Individuals with severe heart failure (NY Heart Association class III and IV), myocardial infarction, unstable angina, aortic dissection and cerebrovascular stenosis
- Individuals in a deep coma
- Individuals with resistant hypertension [systolic BP ≥170 mm Hg despite use of 4 or more antihypertensive medications for half a year or longer]
- Intravenous thrombolytic therapy (such as intravenous rtPA)
- Individuals who are unable to participate in follow-up examination
- Current pregnant women
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China
This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.
Read the detailed description
We designed a randomized controlled clinical trial to test:
- The effectiveness of blood pressure reduction among patients with acute ischemic stroke (within 48 hours of onset) on the primary outcome, a combination of death within 14 days after randomization and dependency (modified Rankin scale ≥3) at 14 day or at the time of discharge, if that occurred before 14 days.
- The effectiveness of blood pressure reduction among patients with acute ischemic stroke (within 48-hours of onset) on secondary outcomes:
- Combination of all-cause mortality and dependency over 3, 12, and 24 months of follow-up
- Combined vascular disease events over 3, 12, and 24 months of follow-up (vascular deaths, non-fatal stroke, non-fatal myocardial infarction, coronary revascularization, hospitalized or treated angina, hospitalized or treated congestive heart failure, and hospitalized or treated peripheral arterial disease)
- Recurrent fatal and non-fatal stroke over 3, 12, and 24 months of follow-up
- Neurological functional status measured by NIH Stroke Score and modified Rankin scale at 14 day or discharge after randomization, and over 3, 12, and 24 months of follow-up
- All-cause mortality over 3, 12, and 24 months of follow-up
- Duration of initial hospitalization
- Changes in systolic and diastolic blood pressure within 24 hours and over 7 days, and 14 days
- Conditions
- Ischemic Stroke
- Being tested
- Active antihypertensive treatment
- Keywords
- Ischemic stroke, Hypertension, Antihypertensive Agents, Randomized Controlled Trial
- Medical subject headings
- Ischemic Stroke, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active antihypertensive treatmentOther
Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
| Study group | Role | What they receive |
|---|---|---|
| Active antihypertensive treatment | Experimental | Active antihypertensive treatment Receives: Other: Active antihypertensive treatment |
| Usual care | No intervention | Discontinue all home BP medications. |
What is being measured
The primary outcome is the main question the study is designed to answer.
A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days.
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death.
Measured: 2 weeks
Secondary outcomes (8)
A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death
Measured: 3 months
Mortality
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained.
Measured: 3 months
Recurrent Stroke
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected.
Measured: 3 months
Other Vascular Events
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected.
Measured: 3 months
Long-term Neurological and Functional Status
Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale.
Measured: Three months
Cognitive Function (the Mini-Mental State Examination)
Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment).
Measured: Three months
Cognitive Function (Montreal Cognitive Assessment)
Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26.
Measured: Three months
Quality of Life
Due to limited funding, quality of life data were not collected.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2013 (estimated)
- Study startAug 2009
- Primary completionMay 2013
- Study completionMay 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (35)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 4,071 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tulane University
- Sponsor type
- University, hospital or other
- Collaborators
- Soochow University
- Responsible party
- Principal investigator, Jiang He, MD, PhD, Tulane University
- Investigators
- Jiang He, MD, PhD, Principal investigator, Tulane University SPHTM
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01840072
- Sponsor's protocol ID
- 140815
- Acronym
- CATIS
- Status last verified
- Mar 2024
- First submitted
- 13 Apr 2013
- Last updated
- 27 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Bu X, Li C, Zhang Y, Xu T, Wang D, Sun Y, Peng H, Xu T, Chen CS, Bazzano LA, Chen J, He J; CATIS Investigators. Early Blood Pressure Reduction in Acute Ischemic Stroke with Various Severities: A Subgroup Analysis of the CATIS Trial. Cerebrovasc Dis. 2016;42(3-4):186-95. doi: 10.1159/000444722. Epub 2016 Apr 26.
PubMed 27110711Zhong C, Xu T, Xu T, Peng Y, Wang A, Wang J, Peng H, Li Q, Geng D, Zhang D, Zhang Y, Zhang Y, Gao X, He J; CATIS Investigation Groups. Plasma Homocysteine and Prognosis of Acute Ischemic Stroke: a Gender-Specific Analysis From CATIS Randomized Clinical Trial. Mol Neurobiol. 2017 Apr;54(3):2022-2030. doi: 10.1007/s12035-016-9799-0. Epub 2016 Feb 24.
PubMed 26910818He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, Peng Y, Peng H, Li Q, Geng D, Zhang J, Li D, Zhang F, Guo L, Sun Y, Wang X, Cui Y, Li Y, Ma D, Yang G, Gao Y, Yuan X, Bazzano LA, Chen J; CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014 Feb 5;311(5):479-89. doi: 10.1001/jama.2013.282543.
PubMed 24240777Bu X, Zhang Y, Bazzano LA, Xu T, Guo L, Wang X, Zhang J, Cui Y, Li D, Zhang F, Ju Z, Xu T, Chen CS, Chen J, He J. Effects of early blood pressure reduction on cognitive function in patients with acute ischemic stroke. Int J Stroke. 2016 Dec;11(9):1009-1019. doi: 10.1177/1747493016660094. Epub 2016 Jul 13.
PubMed 27412188Qin S, Wang M, Zhu Y, Wu S, Du M, Peng Y, Xu T, Zhang Y, Xu X, Zhong C, Xiao G. Plasma Glutamine and Glutamate in Relation to Clinical Outcomes After Ischemic Stroke: A Multicenter Prospective Study. J Am Heart Assoc. 2026 Oct 10:e049903. doi: 10.1161/JAHA.126.049903. Online ahead of print.
PubMed 42858005Zhao W, Sun L, Zan J, Zheng X, Zhou J, Yang X, Zhang Y, Shi M, Xu T. Plasma Cluster of Differentiation 147 and Cognitive Impairment After Acute Ischemic Stroke. J Am Heart Assoc. 2026 Sep 9:e048033. doi: 10.1161/JAHA.125.048033. Online ahead of print.
PubMed 42714478Yang P, Sun L, Jia Y, Zhu Z, Wang A, Zhang Y, Xu T, Su L. Serum S100B and Its Interplay With hs-CRP and Platelet Count in Association With Adverse Outcomes After Ischemic Stroke. J Am Heart Assoc. 2026 Aug 20:e048160. doi: 10.1161/JAHA.125.048160. Online ahead of print.
PubMed 42622219Zong Z, Zhou C, Guo H, Cao M, Wu S, Xu T, Zhang Y, Zhong C, Liu H. Plasma choline and betaine and neurological function trajectory after acute ischemic stroke. BMC Neurol. 2026 Jun 30. doi: 10.1186/s12883-026-05132-9. Online ahead of print.
PubMed 42374230Zhong C, Wang M, Liu D, Wei Y, Wang M, Peng Y, Chen J, Pan Y, Xu T, Wang Y, He J, Wang Y, Zhang Y, Liu L, Xie X. Antihypertensive Treatments After Acute Ischemic Stroke: to Continue or Not? Hypertension. 2026 Feb;83(2):e25575. doi: 10.1161/HYPERTENSIONAHA.125.25575. Epub 2025 Dec 5.
PubMed 41347304Wang M, Long J, Yuan K, Cao M, Peng Y, Xu T, He J, Zhang Y, Zhong C, Zhai G. Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Promising Biomarker for Poststroke Depression After Acute Ischemic Stroke. J Am Heart Assoc. 2025 Sep 16;14(18):eJAHA2024040555T. doi: 10.1161/JAHA.124.040555. Epub 2025 Aug 22.
PubMed 40847526Wang M, Zhu S, Long J, Cao M, Peng Y, Chen J, Xu T, He J, Zhang Y, Zhong C. Efficacy of immediate anti-hypertensive treatment in patients with acute ischaemic stroke stratified by mean arterial pressure and pulse pressure: a secondary analysis of the China Antihypertensive Trial in Acute Ischemic Stroke trial. Stroke Vasc Neurol. 2025 Dec 23;10(6):743-751. doi: 10.1136/svn-2024-003896.
PubMed 40268338Wang Z, Zhang K, Zhong C, Zhu Z, Zheng X, Yang P, Che B, Lu Y, Zhang Y, Xu T. Plasma human cartilage glycoprotein-39 and depressive symptoms among acute ischemic stroke patients. Gen Hosp Psychiatry. 2025 May-Jun;94:120-125. doi: 10.1016/j.genhosppsych.2025.03.003. Epub 2025 Mar 6.
PubMed 40068363Wang Z, Zhang K, Zhong C, Zhu Z, Zheng X, Yang P, Che B, Lu Y, Zhang Y, Xu T. Plasma Human Cartilage Glycoprotein-39 and Cognitive Impairment After Acute Ischemic Stroke. J Am Heart Assoc. 2025 Jan 21;14(2):e036790. doi: 10.1161/JAHA.124.036790. Epub 2025 Jan 17.
PubMed 39819010He Y, Jia Y, Liu Y, Chang X, Yang P, Shi M, Guo D, Peng Y, Chen J, Wang A, Xu T, He J, Zhang Y, Zhu Z. High Plasma Polyamine Levels Are Associated With an Increased Risk of Poststroke Cognitive Impairment: A Multicenter Prospective Study From CATIS. J Am Heart Assoc. 2025 Jan 21;14(2):e037465. doi: 10.1161/JAHA.124.037465. Epub 2025 Jan 16.
PubMed 39817544Sun L, Zhang Q, Shi M, Liu Y, Zhu Z, Zhang J, Peng H, Wang A, Chen J, Xu T, Zhang Y, He J. Associations Between Gene Variants of Lipid-Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke. J Am Heart Assoc. 2024 Nov 19;13(22):e036544. doi: 10.1161/JAHA.124.036544. Epub 2024 Nov 15.
PubMed 39547981
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China
- ClinicalTrials.gov ID
- NCT01840072
- Acronym / sponsor ID
- CATIS / 140815
- Conditions
- Ischemic Stroke
- Keywords
- Ischemic stroke, Hypertension, Antihypertensive Agents, Randomized Controlled Trial
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4,071 participants (actual)
- Lead sponsor
- Tulane UniversityUniversity, hospital or other
- Collaborators
- Soochow University
- Study start
- Aug 2009
- Primary completion
- May 2013 (actual)
- Study completion
- May 2016 (actual)
- First posted
- 25 Apr 2013 (estimated)
- Results
- Posted 20 Nov 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.
Detailed description
We designed a randomized controlled clinical trial to test:
- The effectiveness of blood pressure reduction among patients with acute ischemic stroke (within 48 hours of onset) on the primary outcome, a combination of death within 14 days after randomization and dependency (modified Rankin scale ≥3) at 14 day or at the time of discharge, if that occurred before 14 days.
- The effectiveness of blood pressure reduction among patients with acute ischemic stroke (within 48-hours of onset) on secondary outcomes:
- Combination of all-cause mortality and dependency over 3, 12, and 24 months of follow-up
- Combined vascular disease events over 3, 12, and 24 months of follow-up (vascular deaths, non-fatal stroke, non-fatal myocardial infarction, coronary revascularization, hospitalized or treated angina, hospitalized or treated congestive heart failure, and hospitalized or treated peripheral arterial disease)
- Recurrent fatal and non-fatal stroke over 3, 12, and 24 months of follow-up
- Neurological functional status measured by NIH Stroke Score and modified Rankin scale at 14 day or discharge after randomization, and over 3, 12, and 24 months of follow-up
- All-cause mortality over 3, 12, and 24 months of follow-up
- Duration of initial hospitalization
- Changes in systolic and diastolic blood pressure within 24 hours and over 7 days, and 14 days
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active antihypertensive treatment | Experimental | Other: Active antihypertensive treatmentActive antihypertensive treatment |
| Usual care | No intervention | –Discontinue all home BP medications. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥22 years
- Ischemic stroke onset within 48 hours confirmed by imaging (CT scan or MRI) study
- Systolic BP≥140 and <220 mm Hg and diastolic BP≥80 mm Hg
- No contraindications to antihypertensive treatment
- Able and willing to sign informed consent by patients or their direct family members
Key exclusion criteria (7 listed)
- Individuals with hemorrhagic stroke
- Individuals with severe heart failure (NY Heart Association class III and IV), myocardial infarction, unstable angina, aortic dissection and cerebrovascular stenosis
- Individuals in a deep coma
- Individuals with resistant hypertension [systolic BP ≥170 mm Hg despite use of 4 or more antihypertensive medications for half a year or longer]
- Intravenous thrombolytic therapy (such as intravenous rtPA)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active antihypertensive treatmentInitial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization. | Other | Active antihypertensive treatment |
Primary outcome
A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days.
Time frame: 2 weeks
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death.
8 secondary outcomes
A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.
Time frame: 3 months
Mortality
Time frame: 3 months
Recurrent Stroke
Time frame: 3 months
Other Vascular Events
Time frame: 3 months
Long-term Neurological and Functional Status
Time frame: Three months
Cognitive Function (the Mini-Mental State Examination)
Time frame: Three months
Cognitive Function (Montreal Cognitive Assessment)
Time frame: Three months
Quality of Life
Time frame: 3 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 27110711Bu X, Li C, Zhang Y, Xu T, Wang D, Sun Y, Peng H, Xu T, Chen CS, Bazzano LA, Chen J, He J; CATIS Investigators. Early Blood Pressure Reduction in Acute Ischemic Stroke with Various Severities: A Subgroup Analysis of the CATIS Trial. Cerebrovasc Dis. 2016;42(3-4):186-95. doi: 10.1159/000444722. Epub 2016 Apr 26.
- Results publication: PubMed 26910818Zhong C, Xu T, Xu T, Peng Y, Wang A, Wang J, Peng H, Li Q, Geng D, Zhang D, Zhang Y, Zhang Y, Gao X, He J; CATIS Investigation Groups. Plasma Homocysteine and Prognosis of Acute Ischemic Stroke: a Gender-Specific Analysis From CATIS Randomized Clinical Trial. Mol Neurobiol. 2017 Apr;54(3):2022-2030. doi: 10.1007/s12035-016-9799-0. Epub 2016 Feb 24.
- Results publication: PubMed 24240777He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, Peng Y, Peng H, Li Q, Geng D, Zhang J, Li D, Zhang F, Guo L, Sun Y, Wang X, Cui Y, Li Y, Ma D, Yang G, Gao Y, Yuan X, Bazzano LA, Chen J; CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014 Feb 5;311(5):479-89. doi: 10.1001/jama.2013.282543.
- Results publication: PubMed 27412188Bu X, Zhang Y, Bazzano LA, Xu T, Guo L, Wang X, Zhang J, Cui Y, Li D, Zhang F, Ju Z, Xu T, Chen CS, Chen J, He J. Effects of early blood pressure reduction on cognitive function in patients with acute ischemic stroke. Int J Stroke. 2016 Dec;11(9):1009-1019. doi: 10.1177/1747493016660094. Epub 2016 Jul 13.
- Derived from this study: PubMed 42858005Qin S, Wang M, Zhu Y, Wu S, Du M, Peng Y, Xu T, Zhang Y, Xu X, Zhong C, Xiao G. Plasma Glutamine and Glutamate in Relation to Clinical Outcomes After Ischemic Stroke: A Multicenter Prospective Study. J Am Heart Assoc. 2026 Oct 10:e049903. doi: 10.1161/JAHA.126.049903. Online ahead of print.
- Derived from this study: PubMed 42714478Zhao W, Sun L, Zan J, Zheng X, Zhou J, Yang X, Zhang Y, Shi M, Xu T. Plasma Cluster of Differentiation 147 and Cognitive Impairment After Acute Ischemic Stroke. J Am Heart Assoc. 2026 Sep 9:e048033. doi: 10.1161/JAHA.125.048033. Online ahead of print.
- Derived from this study: PubMed 42622219Yang P, Sun L, Jia Y, Zhu Z, Wang A, Zhang Y, Xu T, Su L. Serum S100B and Its Interplay With hs-CRP and Platelet Count in Association With Adverse Outcomes After Ischemic Stroke. J Am Heart Assoc. 2026 Aug 20:e048160. doi: 10.1161/JAHA.125.048160. Online ahead of print.
- Derived from this study: PubMed 42374230Zong Z, Zhou C, Guo H, Cao M, Wu S, Xu T, Zhang Y, Zhong C, Liu H. Plasma choline and betaine and neurological function trajectory after acute ischemic stroke. BMC Neurol. 2026 Jun 30. doi: 10.1186/s12883-026-05132-9. Online ahead of print.
- Derived from this study: PubMed 41347304Zhong C, Wang M, Liu D, Wei Y, Wang M, Peng Y, Chen J, Pan Y, Xu T, Wang Y, He J, Wang Y, Zhang Y, Liu L, Xie X. Antihypertensive Treatments After Acute Ischemic Stroke: to Continue or Not? Hypertension. 2026 Feb;83(2):e25575. doi: 10.1161/HYPERTENSIONAHA.125.25575. Epub 2025 Dec 5.
- Derived from this study: PubMed 40847526Wang M, Long J, Yuan K, Cao M, Peng Y, Xu T, He J, Zhang Y, Zhong C, Zhai G. Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Promising Biomarker for Poststroke Depression After Acute Ischemic Stroke. J Am Heart Assoc. 2025 Sep 16;14(18):eJAHA2024040555T. doi: 10.1161/JAHA.124.040555. Epub 2025 Aug 22.
- Derived from this study: PubMed 40268338Wang M, Zhu S, Long J, Cao M, Peng Y, Chen J, Xu T, He J, Zhang Y, Zhong C. Efficacy of immediate anti-hypertensive treatment in patients with acute ischaemic stroke stratified by mean arterial pressure and pulse pressure: a secondary analysis of the China Antihypertensive Trial in Acute Ischemic Stroke trial. Stroke Vasc Neurol. 2025 Dec 23;10(6):743-751. doi: 10.1136/svn-2024-003896.
- Derived from this study: PubMed 40068363Wang Z, Zhang K, Zhong C, Zhu Z, Zheng X, Yang P, Che B, Lu Y, Zhang Y, Xu T. Plasma human cartilage glycoprotein-39 and depressive symptoms among acute ischemic stroke patients. Gen Hosp Psychiatry. 2025 May-Jun;94:120-125. doi: 10.1016/j.genhosppsych.2025.03.003. Epub 2025 Mar 6.
- Individual participant dataSharing planned: No
Related trials for Ischemic Stroke
Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
Recruiting
A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke
Ischemic Stroke
RecruitingObservational study
Role of EEG in Differentiation Between Ischemic and Hemorrhagic Stroke
Acute Ischemic Stroke, Acute Haemorrhagic Stroke
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 2
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jiang He, MD, PhD principal investigator
Tulane University SPHTM
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active antihypertensive treatment in people with Ischemic Stroke, run by Tulane University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Nov 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01840072, which also lists 35 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2024.